Figure 2 Three distinct mechanisms of activation of

Slides:

Advertisements

Similar presentations

Chapter  Differentiate between the following:  Paracrine  Endocrine  Autocrine.

Advertisements

Cell Signaling: A Molecular View

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 6 Effects of adiponectin on podocyte function

Figure 1 Pre-eclampsia prevents VEGF signalling in endothelial cells

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Cellular processes involved in cancer development

Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Proinflammatory mechanisms in CKD

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Pathways of complement activation

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Nat. Rev. Nephrol. doi: /nrneph

Cell Communication.

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The sensory and secretory function of the L cell

Cell Communication.

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 5 Comparison of outcomes with belimumab or rituximab therapy

Figure 2 Mechanisms of the gut–autonomic

Figure 2 Molecular pathways involved in the regulation of T-cell differentiation and cytokine production Figure 2 | Molecular pathways involved in the.

دکتر مجیری داروساز متخصص فارماکولوژی

Figure 1 Acute kidney injury and chronic kidney disease

Figure 2 Oestrogen receptor signalling pathways

Figure 4 Model of changes in the serum levels

Figure 2 Prevention of antigen–antibody

Figure 1 Oestrogen biosynthesis and production sites in the body

Nat. Rev. Nephrol. doi: /nrneph

Lucky Ch. 13 Signaling at the Cell Surface

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Schematic representation of main EGFR-TKIs resistance mechanisms.

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Specificity of the various epidermal growth factor (EGF)

Figure 3 Differentiation and functional control of T-cell subsets

Figure 4 The molecular configuration of the CD20 molecule

Figure 3 Therapeutic intervention in the complement cascade

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Potential mechanisms of PAR activation by thrombin and aPC

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Loss of the glycocalyx leads to podocyte and kidney injury

Figure 3 Localization of ErbB receptors and ligands within the nephron

Nat. Rev. Nephrol. doi: /nrneph

Notes Cell Communication & Cell Signaling!

Figure 4 Podocyte–endothelial cross talk and activation of heparanase

Figure 1 CD36 structure and post-translational modifications

Figure 1 The VEGF family of growth factors

Nat. Rev. Nephrol. doi: /nrneph

Cell Communication CHAPTER 11.

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Cell-to-Cell Signaling

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Figure 4 Intracellular distribution and

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Bile-acid-induced TGR5 signalling pathways in macrophages

Figure 1 Altered modes of cAMP signalling at PTHR1

Jinhua Tang, Na Liu, Shougang Zhuang Kidney International

Nat. Rev. Nephrol. doi: /nrneph

Cell Signaling: A Molecular View

Presentation transcript:

Figure 2 Three distinct mechanisms of activation of the epidermal growth factor receptor (EGFR) pathway Figure 2 | Three distinct mechanisms of activation of the epidermal growth factor receptor (EGFR) pathway. a | Ligand binding. Soluble ErbB ligands can bind and thereby activate their ErbB receptor (here EGFR) in an endocrine (distant cell), paracrine (neighbouring cell), or autocrine (same cell) way. b | Membrane-anchored ligands can activate ErbB receptors (here EGFR) present on membranes of adjacent cells (juxtacrine signalling). c | Transactivation of EGFR by G-protein coupled receptors (GPCRs). Of note, the cytoplasmic tail of the ligand is depicted in panels a and c. Harskamp, L. R. et al. (2016) The epidermal growth factor receptor pathway in chronic kidney diseases Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.91